Le Lézard
Classified in: Health, Science and technology, Business
Subject: JVN

Cognizant is Partnering with Accuray to Accelerate Corporate Transformation and Drive Operational Efficiency in Their Radiation Therapy Business


Partnership Will Support Accuray with SAP S/4HANA Implementation

TEANECK, N.J., June 21, 2023 /PRNewswire/ -- Cognizant (NASDAQ: CTSH) today announced that it is partnering with Accuray Incorporated (NASDAQ: ARAY) to support the company's deployment of SAP S/4HANA to obtain better data and analytics, and achieve greater business efficiencies. Accuray develops, manufactures, and sells radiotherapy systems for the precise, personalized treatment of cancer and certain neurologic conditions. As part of a global agreement, Cognizant is providing planning, design, implementation, change management, and program management for sales, procurement, manufacturing, distribution, installation, and service processes supported by SAP S/4HANA.

The medical technology industry faces pressure to streamline processes and reduce costs while continuing to innovate and introduce new products to market more quickly. Cognizant is working with Accuray to augment its infrastructure with the resources necessary for success.

"Cognizant is a trusted partner whose assistance will help us efficiently and effectively deploy SAP across our global organization. The new Enterprise Resource Planning (ERP) system will provide a platform to streamline and optimize business processes by making available real-time intelligence and insights to inform our decision making. Our team will have the resources needed to become nimbler in the way we operate, ultimately enabling us to enhance our support of the medical professionals involved in patient care," said GS JHA, Global Chief Information Officer and Chief Information Security Officer at Accuray.

"Cognizant is dedicated to partnering with healthcare technology companies focused on the development of lifesaving products," said Surya Gummadi, EVP and President, Cognizant Americas. "We're honored Accuray, a global leader in high-tech, targeted cancer treatment, has chosen Cognizant to help drive operational changes that will enable them to more efficiently develop, deliver and service radiotherapy solutions used worldwide to improve patient care."

About Cognizant
Cognizant (Nasdaq: CTSH) engineers modern businesses. We help our clients modernize technology, reimagine processes and transform experiences so they can stay ahead in our fast-changing world. Together, we're improving everyday life. See how at www.cognizant.com or @cognizant.

For more information, contact:


U.S.

Name Ben Gorelick

Email [email protected]


Europe / APAC

Name Christina Schneider

Email [email protected]


India

Name Rashmi Vasisht

Email [email protected]

 

SOURCE Cognizant Technology Solutions


These press releases may also interest you

at 08:15
MAIA Biotechnology, Inc., ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that independent director Ms. Adelina Louie Ngar Yee made an individual purchase of 19,665...

at 08:15
Ansa Biotechnologies, Inc., the trusted partner for complex DNA synthesis, today announced its speaker lineup for presentations at the upcoming Global Synthetic Biology (SynBioBeta) Conference in San Jose, Calif., from May 6-9, 2024. The company is...

at 08:15
Qlaris Bio, Inc. ("Qlaris"), a clinical-stage biotechnology company targeting unmet needs in debilitating ophthalmic diseases, today announced that it has closed a $24 million Series B financing round. Co-led by Canaan and New Leaf Venture Partners,...

at 08:12
DSFederal, Inc., and its strategic alliance partner, Taiwan AI Labs, are excited to announce their participation in the upcoming AI Expo for National Competitiveness scheduled to take place on May 7-8 at the Walter E. Washington Convention Center in...

at 08:10
Desktop Health ? the trusted production-grade medical 3D printing brand of Desktop Metal, Inc. ? and Asiga, a leading dental 3D printing brand, have validated Flexcera Smile Ultra+, Flexcera Smile, and Flexcera Base for use on the Asiga 3D printing...

at 08:10
Aurion Biotech, whose mission is to restore vision to millions of patients with life-changing regenerative therapies, today announced that it has completed dosing of all subjects in its Phase 1 / 2 clinical trial (CLARA) of AURN001, an allogeneic...



News published on and distributed by: